DKN-01
In human trialsMeasured in people, not heightBy injectionAntibodyAlso sirexatamab
An antibody in cancer trials that removes DKK1, a brake on bone building.
Antibody that neutralises circulating DKK1. Developed in oesophagogastric, gynaecologic and colorectal cancer, where DKK1 is a tumour target.
Risks. In adult cancer trials it was reported as well tolerated, with tiredness, anaemia and raised liver blood tests the common problems alongside an immunotherapy drug. Its trials have all been in adults.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.